3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Gastrointestinal
1
Conditions
Breast Neoplasms
71
Neoplasms
70
Lung Neoplasms
29
Prostatic Neoplasms
26
Head and Neck Neoplasms
22
Colorectal Neoplasms
19
Uterine Cervical Neoplasms
17
Ovarian Neoplasms
13
Neoplasm Metastasis
13
Motor Activity
13
Fatigue
11
Endometrial Neoplasms
11
Colonic Neoplasms
11
Brain Neoplasms
11
Pain
10
Carcinoma, Non-Small-Cell Lung
10
Multiple Myeloma
9
Melanoma
9
Rectal Neoplasms
8
Leukemia
8
Gastrointestinal Neoplasms
8
Smoking Cessation
7
Pancreatic Neoplasms
7
Lymphoma
7
Depression
7
cyclopia sequence
6
Esophageal Neoplasms
6
Carcinoma, Renal Cell
6
Advanced Cancer
6
Uterine Neoplasms
5
Interventions
Cisplatin
30
Pemetrexed
21
Gemcitabine
11
Radiotherapy
6
Nivolumab
6
Drug Therapy
6
Cyclophosphamide
6
Carboplatin
6
durvalumab
4
Vinorelbine
4
Chemotherapy, Adjuvant
4
tumor necrosis factor-alpha, CNGRC fusion protein, human
3
sodium thiosulfate
3
sargramostim
3
Ipilimumab
3
Doxorubicin
3
raltitrexed
2
pembrolizumab
2
cediranib
2
SS1(dsFv)PE38
2
Radiotherapy, Intensity-Modulated
2
Psychiatric Rehabilitation
2
Photochemotherapy
2
Neoadjuvant Therapy
2
Methotrexate
2
Interferon-alpha
2
Imatinib Mesylate
2
Granulocyte-Macrophage Colony-Stimulating Factor
2
Gefitinib
2
Everolimus
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Mesothelioma, Malignant
×
Surveys and Questionnaires
×
Clear all
NCT01126346
2018-07-03
HOPE
Wake Forest University Health Sciences
Phase NA
Completed
10 enrolled